Sandoz Says Allergan Glaucoma Patents Adds 'Nothing New'
Sandoz Inc. and other pharmaceutical companies urged a Federal Circuit panel Thursday to reverse a federal judge's veto of their planned generic version of the glaucoma drug, Lumigan, saying Allergan Inc....To view the full article, register now.
Already a subscriber? Click here to view full article